Company: BIAF
Filing Date: 2025-04-22
Form Type: 424B3
Source: 0001641172-25-005598
Chunk: 66

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-04-22
Form: 424B3
Chunk 66
---
 or new interpretations of existing laws, regulations, or decisions related to healthcare availability, the method of delivery,
or payment for healthcare tests, products, and services could negatively impact our business, operations, and financial condition.

There have been, and likely will continue to be, legislative
and regulatory proposals at the foreign, federal, and state levels directed at broadening the availability of healthcare and containing
or lowering the cost of healthcare, including proposals aimed at lowering prescription drug prices and increasing competition for prescription
drugs, as well as additional regulation on pharmaceutical transparency and reporting requirements, any of which could negatively impact
our future profitability and increase our compliance burden. We cannot predict the initiatives that may be adopted in the future, including
future challenges or significant revisions to the Affordable Care Act. The continuing efforts of the government, insurance companies,
managed care organizations, and other payors to contain or reduce costs of healthcare and/or impose price controls may adversely affect:

| ● | the demand for our diagnostic tests or therapeutic product candidates, if we or our licensors obtain regulatory approval; |
| ● | the ability to set a price that we believe is fair for our diagnostic tests and therapeutic products;                     |
| ● | the ability to obtain coverage and reimbursement approval for a diagnostic test and therapeutic product;                  |
| ● | our ability to generate revenue and achieve or maintain profitability;                                                    |
| ● | the level of taxes that we are required to pay; and                                                                       |
| ● | the availability of capital.                                                                                              |

Any reduction in reimbursement from Medicare or other
government programs may result in a similar reduction in payments from private payors, which may adversely affect our future profitability.

Risks Related to Ownership of Our Common Stock and Warrants

Our failure to meet the continued listing requirements of The Nasdaq Capital Market could result in a de-listing of our Common Stock.

The shares of our Common Stock are listed for trading
on The Nasdaq Capital Market under the symbol “BIAF” and our Tradeable Warrants are listed under the symbol “BIAFW.”
On February 7, 2025, we received written notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”)
notifying us that for the preceding 30 consecutive business days (December 23, 2024, through February 6, 2025), our Common Stock did not
maintain a minimum closing bid price of $1.00 (“Minimum Bid Price Requirement”) per share as required by Nasdaq Listing Rule